NEWS

Filter By
  • 01/11/2023

    University of California Los Angeles

    Researchers from Tempus partnered with the University of California Los Angeles to study the genomic landscape of small cell lung cancer (SCLC) in never smoking patients. The first and largest analysis of a rare subgroup (3-7%) of SCLC patients with no smoking history. Lung cancer in never smokers is a high unmet need due to its rising incidence over the past 20+ years. Historically, most SCLC clinical trials have e...

  • 12/07/2022

    MD Anderson Cancer Center & Dana–Farber Cancer Institute

    Researchers from Tempus partnered with MD Anderson Cancer Center and the Dana-Farber Cancer Institute to study the value of germline testing in patients with advanced cancer.  Recent studies have found that 12-17% of cancer patients carry pathogenic germline variants (genetic alterations) that translate to cancer predisposition. Despite this, many cancer patients do not meet guidelines for testing and these germline pathogenic variants go undetect...

  • image description

    Ayala Pharmaceuticals

    As part of a larger collaboration, Ayala Pharmaceuticals has chosen Tempus as the preferred sequencing partner to support in screening and recruiting patients for its TENACITY AL101 study, a therapy targeting triple negative breast cancer. The collaboration aims to identify patients with various NOTCH alterations to accurately match and enroll them into the TENACITY trial operating in the U.S., Euro...